Improving Outcomes in Cardiogenic Shock: A Focus on Reducing Complications
Cardiogenic shock (CS) is a complex hemodynamic syndrome resulting from reduced cardiac output, and with inordinately high mortality, 50% or more, despite meaningful advances in treatment.1 Use of tMCS, including veno-arterial extracorporeal membrane oxygenation with and without addition of a microaxial flow pump (mAFP) or Impella device, has increased substantially over the last decade, likely due to advances in device technology.2 In the current issue of the Journal, Ott et al. shed more light on the impact of complications on CS mortality in patients treated with tMCS stratified by device type used.
